실적분석 Ascendis Pharma ($ASND) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat, Shares Rise After-Hours on Core Business Growth
Earnings Scorecard
Revenue: €339 million (approximately +115% year-over-year, vs. €330 million estimate) ✅ Beat
EPS: Adjusted diluted €0.90 (vs. $0.77 estimate) ✅ Beat
Guidance: Not provided — the press release does not include next-quarter or full-year revenue or EPS outlook
Stock reaction: After-hours +3.34% ($264) — as of 20:46 KST, 08-13
The Positives
Product revenue up 105%: Q2 product revenue of €315 million, more than double the prior-year period
Skytrofa leads the way: Flagship product revenue of €252 million drove growth
Adjusted profit expands: Adjusted operating profit of €92 million, 27% margin
Demand for treatments of rare endocrine diseases continued, and as a commercial-stage biopharma company, top-line growth is clearly accelerating. Patient enrollment for new product Yorvipad in the US has also begun, signaling a broadening product portfolio.
The Negatives
Heavy one-off contribution: The €158 million sale of priority review vouchers inflated operating profit
Sharp SG&A increase: SG&A of €173 million, up significantly from €108 million a year earlier
No financial guidance: Next-quarter and full-year revenue and EPS outlook were not provided
Reported IFRS net income looks large, but stripping out one-off items such as the priority review voucher sale shrinks the underlying profit picture. With global launch costs continuing to climb, how well core margins are maintained will be the key question.
What Management Said
Management emphasized that the patient-focused strategy has driven demand for TransCon products and milestone achievement. The tone was that a pipeline targeting unmet medical needs will underpin long-term growth in rare endocrine diseases and new therapeutic areas.
Market Reaction and What to Watch Next
With steep product revenue growth and an early traction signal for the new product confirmed, buyers appeared to place greater weight on core momentum than on the one-off profit contribution.
Watch whether Skytrofa continues to attract new patients and expand internationally.
Monitor the pace of Yorvipad's US prescriptions and reimbursement progress, along with the European approval outcome.
Check whether operating cash flow continues to build steadily following the priority review voucher sale.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
Today's 5 AI picks, all free